Výsledky vyhledávání - "L. M. Larratt"

Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations

Autor: W P, Gati, L M, Larratt, A R, Turner

Publikováno v: Proceedings of the Western Pharmacology Society. 44

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2f6b1ffeb3c9270bf7defb33a23658a8
https://pubmed.ncbi.nlm.nih.gov/11794010

Zobrazit plný text záznamu

Recurrent Epstein-Barr virus associated disease in a cardiac transplant patient: evolution from plasmacytic hyperplasia to diffuse large cell lymphoma

Autor: L M, Larratt, M, Hamilton, R, Coupland, J K, Preiksaitis

Publikováno v: Transplant infectious disease : an official journal of the Transplantation Society. 3(2)

An Epstein-Barr virus (EBV)-seronegative 31-year-old male underwent cardiac transplantation in 1991 for congenital cardiomyopathy. He presented with a protracted course of waxing and waning lymphadenopathy beginning four years after transplantation w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aeb26a4c33d53b24f46ade2147187438
https://pubmed.ncbi.nlm.nih.gov/11400706

Zobrazit plný text záznamu

Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency

Autor: M J, Mant, A R, Turner, D, Bruce, C, Ritchie, L M, Larratt

Publikováno v: American journal of hematology. 62(1)

Some patients with thrombotic thrombocytopenic purpura (TTP) remain plasma-exchange-dependent for prolonged periods of time. This exposes patients to risk, uses substantial resources, and requires prolonged hospitalization. We have splenectomized 7 s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9dd85af6c8097977ddd586922ee35a44
https://pubmed.ncbi.nlm.nih.gov/10815796

Zobrazit plný text záznamu

Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells

Autor: A, Janowska-Wieczorek, L A, Marquez, A, Matsuzaki, H R, Hashmi, L M, Larratt, L M, Boshkov, A R, Turner, M C, Zhang, D R, Edwards, A E, Kossakowska

Publikováno v: British journal of haematology. 105(2)

We compared the expression of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in bone marrow acute myelogenous leukaemia (AML) blasts and leukaemic cell lines (HEL, HL-60, K-562 and KG-1) wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2952f92521d393b57a2c2f127d3639bf
https://pubmed.ncbi.nlm.nih.gov/10233411

Zobrazit plný text záznamu

Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein

Autor: W P, Gati, A R, Paterson, L M, Larratt, A R, Turner, A R, Belch

Publikováno v: Blood. 90(1)

Cytarabine (araC) is converted to araC 5'-triphosphate after entering leukemia cells as a substrate for nucleoside transport processes. This study tested the relationship between araC cytotoxicity, measured in an in vitro tetrazolium dye reduction as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::edb57e0d64dd2d516530669531ad2bfa
https://pubmed.ncbi.nlm.nih.gov/9207471

Zobrazit plný text záznamu

A Multicenter Randomized Trial Comparing Response-Adapted (RA), Non-Cross-Resistant Induction and Consolidation with Idarubicin/Cytarabine (IDAC) Followed by Mitoxantrone/Etoposide (NOVE) Compared with Consolidation with High Dose Cytarabine (HDAC) in Adult Patients with AML. A Study by the Canadian Leukemia Studies Group (CLSG)

Autor: E. Yetisir, K. S. Robinson, D. P. Sheridan, Richard van der Jagt, L. M. Larratt, George A. Wells, R. Delage

Publikováno v: Blood. 106:4619-4619

Background: A CLSG pilot rx’d 140 pts.with Response Adapted Rx(RA) with Idarubicin 12 mg/m2 d1-3 & Ara-C 200 mg/m2 d1-7(IDAC);followed by IDAC II, then Mitoxantrone10 mg/m2&VP-16 100 mg/m2d1-5(NOVE), if in CR after IDAC, & NOVE x2 if they had persi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3856687ad3eddd767599264cb763154
https://doi.org/10.1182/blood.v106.11.4619.4619

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání